bluebird bio, Inc. (NASDAQ:BLUE) Given Average Rating of “Hold” by Analysts

bluebird bio, Inc. (NASDAQ:BLUE) has been given an average rating of “Hold” by the eleven brokerages that are covering the firm, MarketBeat.com reports. Two analysts have rated the stock with a sell rating, seven have issued a hold rating and two have assigned a buy rating to the company. The average twelve-month target price among brokerages that have issued a report on the stock in the last year is $3.03.

Several brokerages recently commented on BLUE. Wells Fargo & Company decreased their price target on bluebird bio from $3.00 to $2.00 and set an “equal weight” rating on the stock in a research note on Wednesday, September 25th. StockNews.com started coverage on shares of bluebird bio in a research note on Tuesday. They issued a “sell” rating on the stock. Barclays lowered their target price on shares of bluebird bio from $4.00 to $2.00 and set an “overweight” rating on the stock in a report on Friday, November 15th. Bank of America downgraded shares of bluebird bio from a “buy” rating to a “neutral” rating and cut their price target for the company from $3.00 to $0.50 in a report on Friday, November 15th. Finally, JPMorgan Chase & Co. cut shares of bluebird bio from a “neutral” rating to an “underweight” rating in a research note on Friday, November 15th.

bluebird bio Stock Up 2.1 %

BLUE stock opened at $0.38 on Friday. The business’s 50-day simple moving average is $0.45 and its 200 day simple moving average is $0.75. The company has a quick ratio of 0.33, a current ratio of 0.51 and a debt-to-equity ratio of 0.37. The company has a market cap of $73.46 million, a PE ratio of -0.20 and a beta of 0.76. bluebird bio has a twelve month low of $0.29 and a twelve month high of $5.53.

bluebird bio (NASDAQ:BLUE) last released its quarterly earnings data on Friday, September 13th. The biotechnology company reported ($0.36) EPS for the quarter. The business had revenue of $18.57 million for the quarter. bluebird bio had a negative return on equity of 322.46% and a negative net margin of 565.74%. On average, research analysts anticipate that bluebird bio will post -1.35 earnings per share for the current year.

Institutional Trading of bluebird bio

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. SG Americas Securities LLC lifted its stake in shares of bluebird bio by 458.8% during the first quarter. SG Americas Securities LLC now owns 80,032 shares of the biotechnology company’s stock valued at $102,000 after acquiring an additional 65,710 shares during the period. Vanguard Group Inc. lifted its position in bluebird bio by 19.6% during the 1st quarter. Vanguard Group Inc. now owns 10,498,460 shares of the biotechnology company’s stock valued at $13,438,000 after purchasing an additional 1,723,081 shares during the period. American International Group Inc. boosted its stake in shares of bluebird bio by 77.4% in the 1st quarter. American International Group Inc. now owns 94,371 shares of the biotechnology company’s stock valued at $121,000 after purchasing an additional 41,177 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its stake in shares of bluebird bio by 113.7% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 54,714 shares of the biotechnology company’s stock valued at $71,000 after purchasing an additional 29,113 shares during the last quarter. Finally, Bayesian Capital Management LP acquired a new stake in shares of bluebird bio during the 1st quarter worth approximately $52,000. Institutional investors and hedge funds own 87.43% of the company’s stock.

bluebird bio Company Profile

bluebird bio, Inc, a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy.